Camilla Parker Bowles dismisses AstraZeneca vaccine concerns

Camilla Parker-Bowles has shared that she received the AstraZeneca vaccine, amid unconfirmed fears it causes blood clots. 

• Camilla Parker Bowles has revealed she received the AstraZeneca vaccine for Covid-19.
• The Duchess of Cornwall shrugged off fears that the vaccine is linked to blood clots, saying, “You take what you are given.” 
• In other Royal News, Prince Philip makes first statement since leaving hospital as he arrives at Windsor Castle.
  

Camilla Parker-Bowles has dismissed the skepticism of the AstraZeneca vaccine for Covid-19, following recent concerns it may cause health problems.

Several European countries, including Denmark, Norway, and Ireland, have suspended the distribution of the British-Swedish drug after fears it was linked to blood clots. The EU has refuted these claims, which have yet to be substantiated by evidence. 

The Duchess of Cornwall was quick to share her take on the controversy during her recent visit to vaccination facility at Finsbury Park Mosque in London. “I had the AstraZeneca,” she told reporters. “Although it didn’t matter, I didn’t ask. You take what you are given.” 

Camilla and her husband Prince Charles were two of the first members of the royal family to be vaccinated, receiving the life-saving jab in February. Prince Charles had contracted Covid-19 last spring but fortunately made a full recovery. Camilla did not catch the virus, but still followed the NHS guidelines and socially isolated for a period of two weeks as a precaution. 

The countries that have paused the rollout of the AstraZeneca shot have delayed their vaccination timeline. The Danish government had planned to have its entire adult population vaccinated by early July but is now most likely to achieve this goal by mid-August. Ireland has also slowed down the process, after deferring 30,000 appointments for those who were scheduled to receive the AstraZeneca vaccine this week. 

AstraZeneca has responded to the concerns in a statement, in which the company said: “An analysis of our safety data of more than 10 million records has shown no evidence of an increased risk of pulmonary embolism or deep vein thrombosis in any defined age group, gender, batch or in any particular country with Covid-19 Vaccine AstraZeneca. In fact, the observed number of these types of events is significantly lower in those vaccinated than what would be expected among the general population.”